Literature DB >> 28275501

Who are appropriate surgical candidates among patients with oligometastatic non-small cell lung cancer?

Tomoyuki Hishida1.   

Abstract

Entities:  

Year:  2017        PMID： 28275501      PMCID： PMC5334073          DOI： 10.21037/jtd.2017.02.25

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  9 in total

1.  Oligometastases.

Authors:  S Hellman; R R Weichselbaum
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

Review 2.  New Strategies in Stereotactic Radiotherapy for Oligometastases.

Authors:  David A Palma; Alexander V Louie; George B Rodrigues
Journal:  Clin Cancer Res       Date:  2015-12-01       Impact factor: 12.531

3.  Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer.

Authors:  Katelyn K Johnson; Joshua E Rosen; Michelle C Salazar; Daniel J Boffa
Journal:  Ann Thorac Surg       Date:  2016-06-23       Impact factor: 4.330

4.  Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).

Authors:  Dirk De Ruysscher; Rinus Wanders; Angela van Baardwijk; Anne-Marie C Dingemans; Bart Reymen; Ruud Houben; Gerben Bootsma; Cordula Pitz; Linda van Eijsden; Wiel Geraedts; Brigitta G Baumert; Philippe Lambin
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

5.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Authors:  Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

Review 6.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.

Authors:  Wilfried E E Eberhardt; Alan Mitchell; John Crowley; Haruhiko Kondo; Young Tae Kim; Andrew Turrisi; Peter Goldstraw; Ramon Rami-Porta
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

7.  Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Mark A Socinski; Tracey Evans; Scott Gettinger; Thomas A Hensing; Lecia VanDam Sequist; Belinda Ireland; Thomas E Stinchcombe
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

8.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316

Review 9.  Oligometastases and oligo-recurrence: the new era of cancer therapy.

Authors:  Yuzuru Niibe; Kazushige Hayakawa
Journal:  Jpn J Clin Oncol       Date:  2010-01-04       Impact factor: 3.019
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.